m+Medelevator.RU
← Поиск публикаций
Kidney360 · 2026

Vascular Access-Related Heart Failure: Pathophysiological Insights, Diagnostic Challenges, and Management Strategies.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Prajiante Bertolino Enrico, Khan Abdullah, Sorour Ahmed A, Vachharajani Tushar J, Wassif Heba, Finet J Emanuel, Raskin Daniel, Partovi Sasan, Lyden Sean P, Kirksey Lee

Аннотация

Arteriovenous access-related heart failure (ARHF) is a critical yet underrecognized complication in ESKD patients on hemodialysis. Heart failure is highly prevalent among patients with ESKD and is often characterized as uremic cardiomyopathy. In this setting, the increased hemodynamic load imposed by a functioning hemodialysis access circuit can further aggravate the underlying myocardial pathology, potentially precipitating high-output heart failure. Vascular access accounts for 23% of high-output heart failure cases, carrying a 58% five-year mortality rate. Despite its prevalence, ARHF remains underdiagnosed and mismanaged due to a lack of established societal guidelines. This narrative review aims to delineate the complex pathophysiology of ARHF, highlight current diagnostic challenges, identify existing gaps in evidence, and suggest potential methods to enhance its management. Hemodynamic changes are investigated, including increased cardiac output, cardiac remodeling, pulmonary hypertension, and arterial stiffening, alongside non-hemodynamic factors. Diagnostic modalities, including history and physical exam, laboratory cardiac biomarkers, transthoracic echocardiography, vascular duplex ultrasound, magnetic resonance imaging and right heart catheterization are discussed. Management strategies, encompassing preoperative prevention and risk stratification, medical therapies, surgical interventions (e.g., banding), and surveillance protocols, are also outlined. This comprehensive review addresses current evidence gaps and provides clinical guidance to improve ARHF recognition, diagnosis, and management.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты